TY - JOUR
T1 - Biohybrid elastin-like venous valve with potential for in situ tissue engineering
AU - González-Pérez, Fernando
AU - Acosta, Sergio
AU - Rütten, Stephan
AU - Emonts, Caroline
AU - Kopp, Alexander
AU - Henke, Heinz-Werner
AU - Bruners, Philipp
AU - Gries, Thomas
AU - Rodríguez-Cabello, J Carlos
AU - Jockenhoevel, Stefan
AU - Fernández-Colino, Alicia
N1 - Copyright © 2022 González-Pérez, Acosta, Rütten, Emonts, Kopp, Henke, Bruners, Gries, Rodríguez-Cabello, Jockenhoevel and Fernández-Colino.
PY - 2022/9/21
Y1 - 2022/9/21
N2 - Chronic venous insufficiency (CVI) is a leading vascular disease whose clinical manifestations include varicose veins, edemas, venous ulcers, and venous hypertension, among others. Therapies targeting this medical issue are scarce, and so far, no single venous valve prosthesis is clinically available. Herein, we have designed a bi-leaflet transcatheter venous valve that consists of (i) elastin-like recombinamers, (ii) a textile mesh reinforcement, and (iii) a bioabsorbable magnesium stent structure. Mechanical characterization of the resulting biohybrid elastin-like venous valves (EVV) showed an anisotropic behavior equivalent to the native bovine saphenous vein valves and mechanical strength suitable for vascular implantation. The EVV also featured minimal hemolysis and platelet adhesion, besides actively supporting endothelialization in vitro, thus setting the basis for its application as an in situ tissue engineering implant. In addition, the hydrodynamic testing in a pulsatile bioreactor demonstrated excellent hemodynamic valve performance, with minimal regurgitation (<10%) and pressure drop (<5 mmHg). No stagnation points were detected and an in vitro simulated transcatheter delivery showed the ability of the venous valve to withstand the implantation procedure. These results present a promising concept of a biohybrid transcatheter venous valve as an off-the-shelf implant, with great potential to provide clinical solutions for CVI treatment.
AB - Chronic venous insufficiency (CVI) is a leading vascular disease whose clinical manifestations include varicose veins, edemas, venous ulcers, and venous hypertension, among others. Therapies targeting this medical issue are scarce, and so far, no single venous valve prosthesis is clinically available. Herein, we have designed a bi-leaflet transcatheter venous valve that consists of (i) elastin-like recombinamers, (ii) a textile mesh reinforcement, and (iii) a bioabsorbable magnesium stent structure. Mechanical characterization of the resulting biohybrid elastin-like venous valves (EVV) showed an anisotropic behavior equivalent to the native bovine saphenous vein valves and mechanical strength suitable for vascular implantation. The EVV also featured minimal hemolysis and platelet adhesion, besides actively supporting endothelialization in vitro, thus setting the basis for its application as an in situ tissue engineering implant. In addition, the hydrodynamic testing in a pulsatile bioreactor demonstrated excellent hemodynamic valve performance, with minimal regurgitation (<10%) and pressure drop (<5 mmHg). No stagnation points were detected and an in vitro simulated transcatheter delivery showed the ability of the venous valve to withstand the implantation procedure. These results present a promising concept of a biohybrid transcatheter venous valve as an off-the-shelf implant, with great potential to provide clinical solutions for CVI treatment.
U2 - 10.3389/fbioe.2022.988533
DO - 10.3389/fbioe.2022.988533
M3 - Article
C2 - 36213079
SN - 2296-4185
VL - 10
JO - Frontiers in bioengineering and biotechnology
JF - Frontiers in bioengineering and biotechnology
M1 - 988533
ER -